Related Experiment Video
Updated: Jan 13, 2026
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
Published on: August 2, 2016
Enhancing the Oral Bioavailability of a Poorly Soluble Pan-CK2 Kinase Inhibitor: Leveraging a Phosphate Prodrug
Murugaiah A M Subbaiah1, Naveen Manjunath1, Thangeswaran Ramar1
1Department of Medicinal Chemistry (Prodrug Group), Discovery & Development Sciences, Biocon-Bristol Myers Squibb Research and Development Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India.
Abstract:
BMS-135, a preclinical casein kinase 2 (CK2) inhibitor, demonstrated subnanomolar potency, robust cellular antiproliferative activity, and pronounced antitumor efficacy in xenograft models. However, its poor solubility posed significant challenges for oral delivery, leading to low oral bioavailability when administered as a solid suspension. Solution formulations improved exposure at lower doses but failed to support dose escalation, resulting in nonlinear pharmacokinetics and diminished bioavailability at higher doses. To overcome these formulation limitations, this study describes the design and synthesis of direct and linker-enabled phosphate prodrugs, resulting in significantly enhanced solubility and improved oral bioavailability up to 14-fold. PK analyses revealed that systemic exposure was governed by both phosphate cleavage and intermediate hydrolysis rates, with steric factors critically influencing enzymatic activation. These findings support the continued development of BMS-135 as an orally bioavailable anticancer therapeutic and highlight the strategic utility of phosphate prodrugs for facilitating the oral delivery of poorly soluble kinase inhibitors.
Insights
Researchers developed phosphate prodrugs to improve the oral delivery of BMS-135, a casein kinase 2 (CK2) inhibitor. This strategy significantly enhanced solubility and oral bioavailability for potential anticancer therapy.
Area of Science:
- Oncology
- Pharmacology
- Medicinal Chemistry
Background:
- BMS-135 is a potent casein kinase 2 (CK2) inhibitor with demonstrated antitumor activity.
- Poor aqueous solubility of BMS-135 limits its oral bioavailability and therapeutic application.
- Existing formulations (suspensions, solutions) failed to overcome dose-limiting pharmacokinetic challenges.
Purpose of the Study:
- To design and synthesize novel phosphate prodrugs of BMS-135.
- To enhance the solubility and oral bioavailability of BMS-135.
- To evaluate the pharmacokinetic properties and therapeutic potential of BMS-135 prodrugs.
Main Methods:
- Synthesis of direct and linker-enabled phosphate prodrugs of BMS-135.
- In vitro assessment of solubility and antiproliferative activity.
- In vivo pharmacokinetic studies in animal models.
- Analysis of enzymatic cleavage and hydrolysis rates.
Main Results:
- Phosphate prodrugs exhibited significantly enhanced aqueous solubility.
- Oral bioavailability was improved up to 14-fold compared to the parent drug.
- Pharmacokinetics were influenced by phosphate cleavage and hydrolysis rates.
- Steric factors played a critical role in enzymatic activation of prodrugs.
Conclusions:
- Phosphate prodrug strategy effectively overcomes solubility limitations of BMS-135.
- The developed prodrugs demonstrate improved oral bioavailability for potential anticancer therapy.
- Phosphate prodrugs are a viable approach for oral delivery of poorly soluble kinase inhibitors.
Related Concept Videos
01:27Bioavailability Enhancement: Drug Permeability Enhancement
01:22Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
01:16Bioavailability Enhancement: Drug Solubility Enhancement
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
01:21Factors Affecting Dissolution: Drug pKa, Lipophilicity and GI pH
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...
01:27Factors Influencing Drug Absorption: Drug Dissolution